4-week trial of fluticasone propionate + albuterol versus components or placebo in asthma

Phase 3, randomised, double-blind trial of fluticasone propionate and salbutamol in asthma (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Baseline-adjusted post-dose forced expiratory volume in one second area under the effect curve from 0 to 6 hours over 4 weeks and Baseline-adjusted trough forced expiratory volume in one second at week 4. Started Jul 2025; status: completed.